EUROAPI Publishes 2024 Universal Registration Document
EUROAPI has announced the release of its 2024 Universal Registration Document. This important document is now available in ESEF format as filed with the French Autorité des marchés financiers (AMF).
Key Components of the Document
The 2024 Universal Registration Document is comprehensive, offering a detailed overview that includes:
Annual Financial Report
This report encompasses the management report, which includes the Corporate Governance report, sustainability statements, and financial statements for the company, as well as consolidated statements.
Statutory Auditors’ Insights
Included in the document are the statutory auditors’ reports, providing critical evaluations and a special report focused on regulated agreements.
Fee Disclosure Information
Transparency is vital; thus, the document reviews disclosures relating to statutory auditors’ fees, ensuring stakeholders can assess auditor engagements.
Share Buy-Back Program Description
Investors can gain insights into the current share buy-back program, which plays a significant role in the company’s strategy.
Accessing the Report
Individuals interested in reviewing the document can find it on EUROAPI's official website and the AMF's platform, as it is available to the public according to the current regulatory frameworks.
About EUROAPI
EUROAPI stands at the forefront of the pharmaceutical industry, focusing on innovative solutions tailored to meet the growing global demand for active pharmaceutical ingredients. With a robust portfolio of about 200 products, the company excels in providing a variety of technologies while advancing the development of new and transformative molecules through its Contract Development and Manufacturing Organization (CDMO) activities.
The heart of EUROAPI's mission is improving health access worldwide. The dedicated team of 3,430 professionals is inspired daily by the goal of enabling crucial therapies. With strong research and development frameworks and six manufacturing sites across Europe, EUROAPI ensures the highest standards in API manufacturing. The company proudly offers services to a customer base spanning over 80 countries.
EUROAPI's commitment to excellence, while navigating the complexities of the pharmaceutical landscape, continues to solidify its position as a leader in this vital sector.
Contact Information
Media Relations:
Laurence Bollack
Tel.: +33 (0)6 81 86 80 19
Email: mr@euroapi.com
Investor Relations:
Sophie Palliez-Capian
Tel.: +33 (0)6 87 89 33 51
Email: Sophie.palliez@euroapi.com
Frequently Asked Questions
What is the purpose of the Universal Registration Document?
The document provides a comprehensive overview of EUROAPI's financial health, governance, and operational strategies.
Where can I find the 2024 Universal Registration Document?
The document is accessible on EUROAPI's official website as well as on the AMF’s platform.
What key information does the annual financial report include?
It includes the management report, corporate governance report, sustainability statements, and financial statements.
How does EUROAPI contribute to sustainable health solutions?
By innovating active ingredient solutions and ensuring access to essential therapies globally.
What is EUROAPI’s approach to quality manufacturing?
The company emphasizes high-quality manufacturing across all its facilities, complying with regulatory standards while supporting customer needs.
